Drug Trial Radar · NCT07644442
Study on [14C]HMPL-453(FGFR Inhibitor) in Healthy Chinese Adult Male Subjects
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Feb 26, 2025
Primary completion
Mar 14, 2025
Study completion Mar 14, 2025
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the absorption, metabolism and excretion in healthy Chinese male subjects after a single oral dose of \[14C\]HMPL-453
Conditions
- Mass Balance Study
Interventions
HMPL-453Drug
D1: 300 mg/200 µCi \[14C\] HMPL-453 Single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Human Mass balanceTime frame: Day-1 ~Day15
- Human Mass balanceTime frame: Day-1 ~Day15
- Human Mass balanceTime frame: Day-1 ~Day15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.